Continuing Medical Education
The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.
Credit Designation Statement
AACR has designated this live activity for a maximum of 17.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.
Claiming (CME) Credit
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the online CME Request for Credit Survey by April 18, 2024. Certificates will only be issued to those who complete the survey. The Request for Credit Survey will be available via a link on the AACR website and via email. Your CME certificate will be sent to you via email after the completion of the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 17.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To receive ABIM MOC, participants must request MOC in the CME Request for Credit Survey and complete all questions. Once these steps are completed, AACR will submit your completion information via the ACCME’s Program and Activity Reporting System for the purpose of granting MOC points.
Statement of Educational Need, Target Audience, and Learning Objectives
According to the American Cancer Society’s Cancer Facts & Figures 2023, 1,629,474 people in the United States are living with or in remission from a blood cancer. Leukemia, lymphoma and myeloma are expected to cause the deaths of an estimated 57,380 people in the US in 2023 – nearly 10% of all cancer mortality.
Many factors contribute to poor survival rates of blood cancers, including:
- The lack of routine laboratory screening and non-toxic early-stage interventions. A session of the conference on precursor conditions is dedicated to that question.
- Patient access to diagnostic and therapeutic resources and to hematology-oncology experts is unequal even in developed countries. In Australia, a third of projected blood cancer deaths in 2023 could be prevented with best-practice treatment3. Sessions on genomics and molecular diagnostics will demonstrate how precision of prognostic tools can improve efficacy and equality while decreasing therapy costs.
- Therapy resistance due to disease heterogeneity, plasticity and evolution, with often drug- and disease-specific mechanisms at play.
New approaches are necessary to overcome these limitations. The sessions on precision medicine and immunotherapy will articulate new interventions in preclinical, translational and clinical stages of development.
The inaugural Blood Cancer Discovery Symposium will showcase the latest discoveries in blood cancers, a field that has often pioneered breakthroughs for cancer treatments in general. This symposium will feature cutting-edge preclinical and clinical findings with broad implications in the fields of cancer genomics and epigenetics, precursor conditions, tumor microenvironment, immunotherapy and precision medicine.
After participating in this CME activity, physicians should be able to:
- Articulate fundamental principles of oncogenesis in hematopoietic system.
- Demonstrate familiarity with key genetic and epigenetic factors contributing to disease pathogenesis and therapy resistance.
- Utilize immunological, genetic and tissue-level molecular and cellular biomarkers of disease progression and treatment response to formulate new hypotheses and guide therapy decisions.
- Evaluate recent clinical advances made in treating hematologic malignancies.
- Formulate priorities for future research: what are the most important unmet needs and how clinical investigators can contribute to moving the field forward.
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed all financial relationships they have with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products or services used by or on patients. All of the relevant financial relationships for these individuals have been mitigated.
Acknowledgment of Financial or Other Support
This activity is supported by Professional Educational Grants which will be disclosed at the activity.